{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[11,2,11,3],[12,2,12,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910465388103321"]
[null,null,"Titolo",null,"Nanoparticulate drug delivery systems [[electronic resource] ] : strategies, technologies, and applications / / edited by Yoon Yeo"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, N.J., : Wiley, 2013"]
[null,null,"ISBN",null,"1-299-24223-5"]
[{"$nulls":4},"1-118-57054-5"]
[null,null,"Descrizione fisica",null,"1 online resource (326 p.)"]
[null,null,"Disciplina",null,"615.1/9"]
[null,null,"Soggetti",null,"Nanoparticles"]
[{"$nulls":4},"Drug delivery systems"]
[{"$nulls":4},"Pharmaceutical biotechnology"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Nanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications; Contents; Preface; Contributors; 1 Tumor-Targeted Nanoparticles: State-of-the-Art and Remaining Challenges; 1.1 INTRODUCTION; 1.2 FUNCTIONS OF NANOPARTICLES; 1.3 TUMOR-TARGETED NANOPARTICLES; 1.3.1 Passive Targeting; 1.3.2 Active Targeting; 1.3.3 Target-Activated Systems; 1.4 REMAINING CHALLENGES IN THE DEVELOPMENT OF TUMOR-TARGETED NANOPARTICLES; 1.4.1 NP Stability; 1.4.2 Heterogeneous Tumor Vasculature; 1.4.3 NP Distribution in Tumors; 1.4.4 Regulatory Considerations; 1.5 FUTURE PERSPECTIVES"]
[{"$nulls":4},"1.5.1 In Vitro Models1.5.2 In Vivo Models; 1.5.3 New Targets; 1.5.4 New Therapeutic Agents; Acknowledgments; REFERENCES; 2 Applications of Ligand-Engineered Nanomedicines; 2.1 INTRODUCTION; 2.1.1 Nanoparticulate Drug Delivery; 2.1.2 Engineered Nanoparticulate Drug Delivery; 2.2 LIGAND-MEDIATED DELIVERY; 2.2.1 Antibodies; 2.2.2 Peptides and Proteins; 2.2.3 Sugars and Polysaccharides; 2.2.4 Small Molecule Chemicals; 2.3 CURRENT CHALLENGES IN CLINICAL DEVELOPMENT OF LIGAND-MODIFIED NANOMEDICINE; 2.3.1 Nonclinical and Clinical Studies; 2.3.2 Challenges and Future Perspectives; 2.4 CONCLUSIONS"]
[{"$nulls":4},"AcknowledgmentsREFERENCES; 3 Lipid Nanoparticles for the Delivery of Nucleic Acids; 3.1 INTRODUCTION; 3.2 BARRIERS TO SYSTEMIC GENE "]
[{"$nulls":4},"DELIVERY; 3.2.1 Extracellular Barriers; 3.2.2 Intracellular Barriers; 3.3 COMPONENTS OF LNPs; 3.3.1 Cationic Lipid; 3.3.2 Neutral Lipid; 3.3.3 Anionic Lipid; 3.3.4 PEG-Lipid Conjugates; 3.4 FORMULATIONS OF THE LNP FOR NUCLEIC ACIDS ENCAPSULATION; 3.4.1 Self-Assembly; 3.4.2 Detergent Dialysis; 3.4.3 Nanometric Calcium Phosphate/siRNA Precipitation; 3.5 ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS WITH LNPs; 3.5.1 Brain-Targeted Delivery; 3.5.2 Liver-Targeted Delivery"]
[{"$nulls":4},"3.5.3 Lung-Targeted Delivery3.5.4 Kidney-Targeted Delivery; 3.6 CURRENT CHALLENGES TO THE DEVELOPMENT OF LNPs; 3.7 FUTURE PERSPECTIVES; Acknowledgments; REFERENCES; 4 Photosensitive Liposomes as Potential Targeted Therapeutic Agents; 4.1 INTRODUCTION; 4.2 EXPERIMENTAL PROCEDURES; 4.2.1 Materials; 4.2.2 Synthesis of 1-Bromo-3-hexadecylthiobenzene (1); 4.2.3 Synthesis of 9-[3-Hexadecylthiophenyl] anthracene (2); 4.2.4 Synthesis of 9-[3-Hexadecyl-3'-cyanobenzylsulfonium] phenylanthracene Trifluoromethanesulfonate (C16-An-PAG) (3); 4.2.5 Liposome Preparation; 4.2.6 Dynamic Light Scattering"]
[{"$nulls":4},"4.2.7 Photoexcitation Method4.2.8 Calcium Ion Release Assay; 4.2.9 Negative Stain Transmission Electron Microscopy; 4.2.10 Animal Studies; 4.3 RESULTS AND DISCUSSION; 4.3.1 DOPE:LysoPlsC Liposomes Using C16-An-PAG as a Photosensitizer; 4.3.2 PPlsC Liposomes Using Bchl a as a Photosensitizer; 4.3.3 Folate Receptor (FR)-Targeted DPPlsC Liposomes Using AlPcS4-4 as a Photosensitizer; 4.4 CONCLUSIONS; 4.5 PROSPECTS FOR LIGHT-ACTIVATED LIPOSOMAL DRUG DELIVERY; Acknowledgments; REFERENCES; 5 Multifunctional Dendritic Nanocarriers: The Architecture and Applications in Targeted Drug Delivery"]
[{"$nulls":4},"5.1 RECENT ADVANCES IN DENDRITIC NANOMATERIALS"]
[null,null,null,"Sommario/riassunto","\"The use of nanoparticles to deliver drugs to specific cells has substantially increased. This guide offers a thorough, up-to-date reference on nanotechnologies for drug delivery, frankly discussing challenges and limitations with nanoparticulate drug delivery systems. After discussing strategies to further develop these systems, chapters focus on applications like nanoparticles for topical drug delivery and nanomedicine toxicology, along with new techniques and methodologies like NanoCrystal. This up-to-date book offers an invaluable reference to any pharmaceutical researcher interested in nanomedicine\"--"]